Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash & Equivalents (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Cash & Equivalents readings, the most recent being $94.1 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 345.04% to $94.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $94.1 million through Mar 2026, up 345.04% year-over-year, with the annual reading at $12.6 million for FY2025, 51.95% down from the prior year.
  • Cash & Equivalents hit $94.1 million in Q1 2026 for Ovid Therapeutics, up from $12.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $166.7 million in Q1 2022 and bottomed at $12.6 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $48.5 million, with a median of $29.5 million recorded in 2024.
  • The largest annual shift saw Cash & Equivalents tumbled 77.63% in 2022 before it skyrocketed 345.04% in 2026.
  • Ovid Therapeutics' Cash & Equivalents stood at $42.0 million in 2022, then plummeted by 35.64% to $27.0 million in 2023, then dropped by 2.74% to $26.3 million in 2024, then tumbled by 51.95% to $12.6 million in 2025, then skyrocketed by 644.35% to $94.1 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Cash & Equivalents are $94.1 million (Q1 2026), $12.6 million (Q4 2025), and $20.5 million (Q3 2025).